Adlai Nortye Ltd. ADS/$ANL
1D1W1MYTD1Y5YMAX
About Adlai Nortye Ltd. ADS
Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference RAS-targeting therapies: its is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors; Next-generation cancer immunotherapies: its candidates, AN8025 (a tri-functional fusion protein of alphaPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways.
- Ticker
- $ANL
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- -
- Headquarters
- North Brunswick, United States
- Website
- www.adlainortye.com
ANL Metrics
BasicAdvanced
$859M
-
-$0.56
-
-
Price and volume
Market cap
$859M
52-week high
$17.25
52-week low
$0.88
Average daily volume
208K
Financial strength
Current ratio
9.55
Quick ratio
9.241
Long term debt to equity
3.868
Total debt to equity
12.429
Interest coverage (TTM)
-16.99%
Profitability
EBITDA (TTM)
-21.651
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-115.30%
Operating margin (TTM)
-114.09%
Management effectiveness
Return on assets (TTM)
-8.70%
Return on equity (TTM)
-20.23%
Valuation
Price to revenue (TTM)
27.226
Price to book
4
Price to tangible book (TTM)
4
Price to free cash flow (TTM)
-15.706
Free cash flow yield (TTM)
-6.37%
Free cash flow per share (TTM)
-0.849
Growth
Earnings per share change (TTM)
-53.79%
3-year earnings per share growth (CAGR)
-66.07%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.